Caseware UK (AP4) 2024.0.164 2024.0.164 2025-06-302025-06-302024-07-01falseLaboratory services for professional healthcare providers specialising in microbiome reporting and wellness testing, together with research and development of biotechnology1515truetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 12662440 2024-07-01 2025-06-30 12662440 2023-07-01 2024-06-30 12662440 2025-06-30 12662440 2024-06-30 12662440 c:Director1 2024-07-01 2025-06-30 12662440 c:Director3 2024-07-01 2025-06-30 12662440 d:PlantMachinery 2024-07-01 2025-06-30 12662440 d:PlantMachinery 2025-06-30 12662440 d:PlantMachinery 2024-06-30 12662440 d:PlantMachinery d:OwnedOrFreeholdAssets 2024-07-01 2025-06-30 12662440 d:FurnitureFittings 2024-07-01 2025-06-30 12662440 d:FurnitureFittings 2025-06-30 12662440 d:FurnitureFittings 2024-06-30 12662440 d:FurnitureFittings d:OwnedOrFreeholdAssets 2024-07-01 2025-06-30 12662440 d:OfficeEquipment 2024-07-01 2025-06-30 12662440 d:OfficeEquipment 2025-06-30 12662440 d:OfficeEquipment 2024-06-30 12662440 d:OfficeEquipment d:OwnedOrFreeholdAssets 2024-07-01 2025-06-30 12662440 d:ComputerEquipment 2024-07-01 2025-06-30 12662440 d:ComputerEquipment 2025-06-30 12662440 d:ComputerEquipment 2024-06-30 12662440 d:ComputerEquipment d:OwnedOrFreeholdAssets 2024-07-01 2025-06-30 12662440 d:OwnedOrFreeholdAssets 2024-07-01 2025-06-30 12662440 d:CurrentFinancialInstruments 2025-06-30 12662440 d:CurrentFinancialInstruments 2024-06-30 12662440 d:CurrentFinancialInstruments d:WithinOneYear 2025-06-30 12662440 d:CurrentFinancialInstruments d:WithinOneYear 2024-06-30 12662440 d:SharePremium 2025-06-30 12662440 d:SharePremium 2024-06-30 12662440 d:OtherMiscellaneousReserve 2024-07-01 2025-06-30 12662440 d:OtherMiscellaneousReserve 2025-06-30 12662440 d:OtherMiscellaneousReserve 2024-06-30 12662440 d:RetainedEarningsAccumulatedLosses 2025-06-30 12662440 d:RetainedEarningsAccumulatedLosses 2024-06-30 12662440 c:OrdinaryShareClass1 2024-07-01 2025-06-30 12662440 c:OrdinaryShareClass1 2025-06-30 12662440 c:OrdinaryShareClass1 2024-06-30 12662440 c:OrdinaryShareClass2 2024-07-01 2025-06-30 12662440 c:OrdinaryShareClass2 2025-06-30 12662440 c:OrdinaryShareClass2 2024-06-30 12662440 c:FRS102 2024-07-01 2025-06-30 12662440 c:AuditExempt-NoAccountantsReport 2024-07-01 2025-06-30 12662440 c:FullAccounts 2024-07-01 2025-06-30 12662440 c:PrivateLimitedCompanyLtd 2024-07-01 2025-06-30 12662440 d:WithinOneYear 2025-06-30 12662440 d:WithinOneYear 2024-06-30 12662440 d:BetweenOneFiveYears 2025-06-30 12662440 d:BetweenOneFiveYears 2024-06-30 12662440 2 2024-07-01 2025-06-30 12662440 6 2024-07-01 2025-06-30 12662440 e:PoundSterling 2024-07-01 2025-06-30 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 12662440









SALIENT LABS LIMITED







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 30 JUNE 2025

 
SALIENT LABS LIMITED
REGISTERED NUMBER: 12662440

BALANCE SHEET
AS AT 30 JUNE 2025

2025
2024
Notes
£
£

FIXED ASSETS
  

Tangible assets
 4 
1,889
12,800

Investments
 5 
250,000
250,000

  
251,889
262,800

CURRENT ASSETS
  

Stocks
  
171,728
188,742

Debtors: amounts falling due within one year
 6 
320,600
278,152

Cash at bank and in hand
  
72,781
672,296

  
565,109
1,139,190

Creditors: amounts falling due within one year
 7 
(131,040)
(102,801)

NET CURRENT ASSETS
  
 
 
434,069
 
 
1,036,389

TOTAL ASSETS LESS CURRENT LIABILITIES BEING NET ASSETS
  
685,958
1,299,189

  


CAPITAL AND RESERVES
  

Share premium account
  
1,121,598
1,121,598

Other reserves
 9 
250,000
-

Profit and loss account
  
(685,640)
177,591

SHAREHOLDERS' FUNDS
  
685,958
1,299,189


Page 1

 
SALIENT LABS LIMITED
REGISTERED NUMBER: 12662440
    
BALANCE SHEET (CONTINUED)
AS AT 30 JUNE 2025

The Directors consider that the Company is entitled to exemption from audit under Section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with Section 476 of the Companies Act 2006.

The Directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the Board of Directors and were signed on its behalf by: 




Dr M Ciechonska
Dr M Priestman
Director
Director


Date: 19 December 2025
Date:19 December 2025

The notes on pages 3 to 9 form part of these financial statements.

Page 2

 
SALIENT LABS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025

1.


GENERAL INFORMATION

Salient Labs Limited (the "Company") is a private company, limited by shares, incorporated in England and Wales under the Companies Act 2006. Its registered address and principal trading address is The Biscuit Fasctory, Drummond Road, London, SE16 4DG.

2.ACCOUNTING POLICIES

 
2.1

BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

FOREIGN CURRENCY TRANSLATION

Functional and presentation currency

The Company's functional and presentational currency is Sterling.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in Other Comprehensive Income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Profit and Loss Account within either 'Interest Receivable' or 'Interest Payable'. All other foreign exchange gains and losses are presented in profit or loss within 'Administrative Expenses'.

 
2.3

TURNOVER

Turnover is recognised to the extent that it is probable that the economic benefits will flow to the Company and the turnover can be reliably measured. Turnover is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. 

Page 3

 
SALIENT LABS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025

2.ACCOUNTING POLICIES (CONTINUED)

 
2.4

RESEARCH AND DEVELOPMENT

In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight-line basis over their useful economic lives, which range from 3 to 6 years.

If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.

 
2.5

GOVERNMENT GRANTS

Grants are accounted under the accruals model as permitted by FRS 102. Grants relating to expenditure on tangible fixed assets are credited to profit or loss at the same rate as the depreciation on the assets to which the grant relates. The deferred element of grants is included in creditors as deferred income.

Grants of a revenue nature are recognised in the Profit and Loss Account in the same period as the related expenditure.

 
2.6

INTEREST INCOME

Interest income is recognised in profit or loss using the effective interest method.

 
2.7

FINANCE COSTS

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.8

PENSIONS

DEFINED CONTRIBUTION PENSION SCHEME

The Company operates a defined contribution pension scheme for its employees. A defined contribution scheme is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in Other Creditors as a liability in the Balance Sheet. The assets of the plan are held separately from the Company in independently administered funds.

Page 4

 
SALIENT LABS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025

2.ACCOUNTING POLICIES (CONTINUED)

 
2.9

TAXATION

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in Other Comprehensive Income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


 
2.10

TANGIBLE FIXED ASSETS

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Plant and machinery
-
3 years straight line
Leasehold improvements
-
3 years straight line
Office equipment
-
3 years straight line
Computer equipment
-
3 years straight line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

Page 5

 
SALIENT LABS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025

2.ACCOUNTING POLICIES (CONTINUED)

 
2.11

VALUATION OF INVESTMENTS

The Company's investment in unlisted company shares, whose market value can be reliably determined, are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in the Profit and Loss Account for the period. Where market value cannot be reliably determined, such investments are stated at historic cost less impairment charges.

 
2.12

STOCKS

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

 
2.13

DEBTORS

Short-term debtors are measured at transaction price, less any impairment.

 
2.14

CASH AND CASH EQUIVALENTS

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.15

CREDITORS

Short-term creditors are measured at the transaction price. Other financial liabilities are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.


3.


EMPLOYEES

The average monthly number of employees, including the Directors, during the year was 15 (2024 - 15).

Page 6

 
SALIENT LABS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025

4.


TANGIBLE FIXED ASSETS





Plant and machinery
Leasehold improve-ments
Office equipment
Computer equipment
Total

£
£
£
£
£



COST 


At 1 July 2024
1,531,416
101,288
35,308
55,770
1,723,782



At 30 June 2025

1,531,416
101,288
35,308
55,770
1,723,782



DEPRECIATION


At 1 July 2024
1,526,588
101,288
34,837
48,269
1,710,982


Charge for the year on owned assets
4,828
-
471
5,612
10,911



At 30 June 2025

1,531,416
101,288
35,308
53,881
1,721,893



NET BOOK VALUE



At 30 June 2025
-
-
-
1,889
1,889



At 30 June 2024
4,828
-
471
7,501
12,800


5.


FIXED ASSET INVESTMENTS





Unlisted investment

£



COST AND NET BOOK VALUE


At 1 July 2024
250,000



At 30 June 2025
250,000




Page 7

 
SALIENT LABS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025

6.


DEBTORS

2025
2024
£
£


Trade debtors
123,389
53,722

Other debtors
171,929
178,464

Prepayments and accrued income
25,282
45,966

320,600
278,152



7.


CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2025
2024
£
£

Trade creditors
84,038
57,813

Other taxation and social security
21,756
15,322

Other creditors
18,134
20,982

Accruals and deferred income
7,112
8,684

131,040
102,801


Included within other creditors is a year end pension liability of £2,885 (2024 - £5,733).


8.


SHARE CAPITAL

2025
2024
£
£
ALLOTTED, CALLED UP AND FULLY PAID



3,798,325 (2024 - 3,798,325) Ordinary shares of £0.0000001- each
0.38
0.38
229,167 (2024 -229,167) Deferred Ordinary shares of £0.0000001- each
0.02
0.02

0.40

0.40





9.


RESERVES

Other reserves

During the year £250,000 was raised via an ASA agreement which will convert to shares upon the start of the next funding round.

Page 8

 
SALIENT LABS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025

10.


COMMITMENTS UNDER OPERATING LEASES

At 30 June 2025 the Company had future minimum lease payments due under non-cancellable operating leases for each of the following periods:

2025
2024
£
£


Not later than 1 year
120,131
133,623

Later than 1 year and not later than 5 years
180,197
286,027

300,328
419,650

 
Page 9